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Abstract 
Human papillomavirus (HPV) is responsible for almost all of the 530,000 new cases of cervical cancer 
and approximately 266,000 deaths per year. HPV vaccination is an integral component of the World 
Health Organization’s global strategy to fight the disease. However, high vaccine prices enforced 
through patent protection are limiting vaccine expansion, particularly in low- and middle-income 
countries. This raises the question of the patent buyout price for Merck’s HPV vaccines (Gardasil-4 and 
9), which hold 87% of the global HPV vaccine market. It also raises the question about the market 
power from patent protection, that we assess by estimating the ratio of R&D costs for Gardasil and its 
patent value. We estimate the patent buyout price for various groups of countries and in total. The 
estimated global Gardasil patent buyout price in 2020 is between US$ 15.33 – 18.32 billion (in 2018 
US$), the estimated present discounted value of the profit stream for 2007-2028 amounts to US$ 22.29 
– 33.08 billion, and the estimated total R&D cost is between US$ 1.10 – 1.21 billion. Thus, we arrive at 
a ratio of R&D costs to the patent value of the order of 3-5%, suggesting that patent protection 
provides Merck with extraordinarily strong market power. 
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1. Introduction 
By implying high vaccine prices, patent protection is considered one of the main factors limiting the 
expansion of vaccination in developing countries.1 Pharmaceutical companies that develop and 
manufacture vaccines frequently face demands to lower vaccine prices in order to make them 
affordable to poorer countries. The typical counterargument is that lower prices could induce 
companies to withdraw certain vaccines from the market or reduce research and development (R&D) 
investments for new vaccines (Outterson, 2005; Light et al., 2009).  
There are two strategies to promote vaccine R&D: pull programmes that provide financial reward to 
companies that develop successful vaccines and push programmes that provide direct funds for 
research. Pull programmes include prizes, compulsory licensing and patent buyouts whereas push 
programmes include research grants and tax credit (Mueller-Langer, 2013). For lowering prices of 
pharmaceuticals, pull programmes that limit market power of pharmaceutical companies entail larger 
potential. Particularly, patent buyouts by government agencies have been suggested as a possible 
instrument to supply medicines at lower costs and make them affordable to poorer countries via 
licensing production to many competitors (Kremer, 1998). This raises the question of the patent 
buyout price a patent holder would be willing to accept for giving up patent protection, i.e. the present 
discounted value of incumbent’s expected future profits over the remaining patent length.  
In this study, we estimate the patent buyout price for two human papillomavirus (HPV) vaccines, 
Gardasil-4 and Gardasil-9,2 from 2020 onwards, given the current and past pricing strategies by patent 
holder Merck.3 We distinguish the patent buyout prices for low-income countries (LIC), middle-income 
countries (MIC), and high-income countries (HIC), particularly the U.S. Moreover, we estimate the 
global value of the Gardasil innovation at market entry and derive estimates of R&D costs. The ratio of 
R&D costs to the patent value is, in theory, the probability of the innovation under free entry of 
potential innovators in the market. Thus, an implausibly low estimated ratio would indicate that the 
                                                          
1 Vaccines are biological preparations that confer protection against a range of infectious diseases. In addition to 
providing individual and community protection, vaccines also reduce the cost of treatment by decreasing disease 
burden. In African countries alone, nearly 3 million children die every year and approximately 24% of these 
deaths are caused by vaccine preventable diseases (Qazi et al., 2015). 
2 Gardasil-4 was named one of the inventions of the year in 2006 by TIME magazine and has by far the largest 
sales for HPV vaccination. The patent gives Merck exclusive rights to manufacture, distribute and sell Gardasil-4 
in the territories in which the patent is valid (Ooms et al., 2014).  
3 It is important to include high-income countries (the classification of countries follows World Bank, 2019). 
Although patent buyouts for LIC and MIC would be most desirable and could in principle be relatively cheap in 
view of the low revenues in these countries (Outterson, 2005), focussing the patent buyout on these groups of 
countries may be infeasible. First, pharmaceutical companies may be reluctant to this solution because they fear 
(illegal) parallel imports or a black market for generic drugs. They may also fear public debate on (too) high prices 
in HIC, once local patent buyouts make high price-cost margins transparent elsewhere.  
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patent system gives Merck more market power than needed to serve the goal of providing proper 
innovation incentives.  
Our focus on HPV vaccination derives, apart from data availability issues, from its importance for global 
health and the prevalence of HPV related diseases particularly in developing countries. HPV is a group 
that encompasses over 100 virus and 15 of them have been shown to be responsible for almost all 
cases of cervical cancer (Clifford et al., 2005). Globally, around 630 million people are infected with 
HPV and half of women will have an infection by this virus in their lifetime (Merck, 2008). Sexually 
transmitted infection with HPV is the biggest risk factor for development of invasive cervical cancer 
(ICC) in females (McGraw and Ferrante, 2014). In addition, HPV induced anogenital cancers and genital 
warts in males are major causes of morbidity and represent a significant health burden. Furthermore, 
HPV infection has been associated with cancers of the anus, vulva, vagina and penis (Frisch and 
Goodman, 2000; Insinga et al., 2005).4  
On average, there are 530,000 new cases of cervical cancer and approximately 266,000 deaths per 
year with the highest incidence in developing nations where HPV vaccine coverage is low (UNICEF, 
2018). In developing countries, cervical cancer is the largest cause of HPV related deaths with an 
estimated incidence of 40 out of 100,000. In sub-Saharan Africa, approximately 70,722 new cases of 
ICC are reported every year, the highest in the world (Louie et al., 2009). By 2030 cervical cancer is 
projected to cause around 474,000 deaths in women annually and the vast majority (95%) of these 
deaths are expected to be in LIC and MIC (Saxena et al., 2012).5 
Vaccine and drug R&D is divided in two stages, pre clinical (in vitro and in vivo studies) and clinical trials 
(phase I-III). Most of the pre-clinical development of Gardasil-4 was performed by the National Cancer 
Institute (NCI), Georgetown University and University of Queensland who were the first to developed 
virus-like particle (VLP) technology used in the vaccine in the early 1990s (Padmanabhan et al., 2010). 
Merck later acquired the licenses and took the then vaccine candidate to clinical testing (Padmanabhan 
et al., 2010). 
To estimate the R&D costs, we identified each clinical trial sponsored by Merck on 
www.clinicaltrial.gov and calculated the costs based on previous estimations per subject (Light et al., 
2009), clinical trial site and study (Sertkaya et al., 2016). The HPV vaccine patent buyout estimation is 
                                                          
4 In cohort of homosexual males aged 16–20 years 39% tested positive for HPV DNA. Within the subgroup 23% 
tested positive for the HPV subtypes that are covered by Gardasil-4 vaccine (6, 11, 16 and 18) (Zou et al., 2014). 
In another study in South Africa HPV11 was detected in 80% of penile precancerous lesions, HPV16 was detected 
in 62.9% of cancerous lesions and some of the lesions were positive for various HPV types (Lebelo et al., 2014). 
5 In the developed world, by contrast, there has been a steady decline in incidence and mortality caused by 
cervical cancer. For instance, in the U.S. and UK there was a 70% decrease in the mortality due to cervical cancer 
between the last quarter of the 20th century and the first decade of the 21st century. The average incidence of 
cervical cancer, age-adjusted, is 10 out of 100000 per year (McGraw and Ferrante, 2014). 
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based on data for costs of materials, labour costs, capital costs and overhead costs provided by 
Clendinen et al. (2016). Moreover, we employ data for sales and prices in different markets to come 
up with regional profit estimates which we extrapolate in the future for the remaining patent lenghts.  
Our estimated global patent buyout in 2020 for Gardasil vaccines is between US$ 15.33 – 18.32 billion 
in 2018 U.S.$, depending on assumed real annual return to investment in alternative uses and cost 
estimates. The patent value, from market entry to patent expiry, we estimate between US$ 22.29 – 
33.08 billion. These high values reflect our findings of high price-cost margins (mark-up factors) which 
could be around 100 for the U.S. and China and still well above 10 in MIC. For R&D costs for both 
Gardasil vaccines, including an additional 15% as costs of capital, we come up with an estimated range 
between US$ 1.1 – 1.21 billion. The latter two estimates imply a ratio of R&D costs and the patent 
value between 3% and 5%. This suggests that if there were free entry into R&D, the innovation 
probability would be astonishingly low. 
Galasso et al. (2016) proposed an R&D incentive-compatible mechanism for designing a patent-
buyout. However, the mechanism presumes that prices can be manipulated to infer the demand 
function for a pharmaceutical, mitigating applicability (Galasso et al., 2016). Beyond the specific 
vaccine for HPV we consider, our suggested methodology could generally be employed to estimate 
patent buyout prices and to inform policy makers on the profits from innovations in relation to R&D 
costs, with possible implications for price negotiations and adjustment in the patent system. To date, 
most studies that estimate R&D costs relied on self-reported data from confidential pharmaceutical 
companies and industry experts that are impossible to assess for accuracy, representativeness, or 
sensitivity to outliers, arriving at estimates for drug development in the range of US$ 161 million to 
US$ 1.8 billion (Morgan et al., 2011).6 Furthermore, many pharmaceutical companies receive public 
and non-profit funds that confound the estimates on the companies’ own R&D investments (Morgan 
et al., 2011). 
The structure of the paper is as follows. Section 2 discusses the use of vaccines for HPV, who 
manufactures them, sales revenues, HPV patents, and the benefit of HPV vaccines patent buyouts. 
Section 3 presents the methodology. Section 4 shows estimates of prices, doses sold, and variable 
manufacturing costs. Section 5 presents the estimation of operating profits, fixed costs and the total 
patent value of the main HPV vaccine, Gardasil-4. Section 6 presents estimates for R&D costs and 
relates them to the patent value for Gardasil. The last section concludes. 
                                                          
6 Light et al. (2009) calculated the costs of the R&D of Rotavirus vaccine and found that the pharmaceutical 
companies responsible for the development of these vaccines declared higher R&D costs in order to charge 
higher prices. 
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2. Background: Vaccines for HPV and Patent Applications 
Fifteen HPV types have been shown to have oncogenic potential: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73, and 82. One of the challenges to create a vaccine and treatment for HPV is the fact 
that an individual can be infected by more than one HPV type (Choi et al., 2012). Globally, HPV 16 and 
18 are responsible for approximately 70% of all cases of cervical cancer. HPV type 16 causes mainly 
squamous cell carcinoma whereas HPV 18 causes the less aggressive adenocarcinoma (Bosch et al., 
2008). In Africa, HPV 16 and 18 are responsible for 43.7-90.2% of the ICC cases (Louie et al., 2009). 
The standard treatments for early and advanced cervical cancer are surgery, chemotherapy and 
treatment with anti-viral agents such as cisplatin. However, none of these approaches are highly 
effective and there is a high rate of recurrent disease (Diaz-Padilla et al., 2013). The costs of screening, 
treating and follow up are expensive for developed economies and almost prohibitive for developing 
economies that lack financial resources, expertise and infrastructure to provide effective measures.7 
In individuals already infected with HPV the prophylactic vaccine is useless. The reason is that 
prophylactic vaccines only block entry of HPV into cervical epithelial cells whereas therapeutic vaccines 
target the intracellular virus and induce a T-cell-based immunity leading to killer T-cells eliminating 
HPV-infected cells (McKee et al., 2015). By contrast, therapeutic vaccines have the potential for an 
immediate effect in reducing the incidence of HPV infection. Currently there are two promising 
therapeutic vaccines candidates that target HPVE6 and E7 proteins which combine newly developed 
adjuvants, delivery vectors and knowledge of the tumour microenvironment (McKee et al., 2015). 
However, it may take considerable time until effective HPV therapeutic vaccines reach the market (Ma 
et al., 2010). 
 
2.1 Prophylactic HPV Vaccines  
The two most widely used prophylactic vaccines in the market are Gardasil-4 (Merck, NJ, USA) and 
Cervarix (GlaxoSmithKline-GSK, Middlesex, UK). Gardasil-4 was approved for both U.S. and European 
markets in September 2006 whereas Cervarix was approved in September 2007 (EMA, 2009; McKee 
et al., 2015). They target HPV L1 major capsid protein that assemble to form VLPs with a morphology 
similar to the HPV native virions and generate robust antibody responses against the targeted HPV 
                                                          
7 In the U.S., the cost of treating and preventing all HPV associated diseases such as cervical and other HPV 
induced cancers (anal, vaginal, vulvar and penile), oropharyngeal cancer, genital warts and recurrent respiratory 
papillomatosis was estimated to be around US$8.0 billion in 2010. The breakdown of this costs is as follows: 
US$6.6 billion cervical cancer screening and follow-up, US$1.0 billion for treatment of HPV related cancer (US$ 
400 million for cervical cancer and US$ 300 million for oropharyngeal cancer), US$ 300 million for treatment of 
genital warts and US$ 200 million for recurrent respiratory papillomatosis (RRP) (Chesson et al., 2012).  
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types (Ma et al., 2010). Both vaccines contain VLPs for HPV 16 and 18, which cause cervical cancer, but 
Gardasil-4 also has VLPs for HPV 6 and 11, which cause benign genital warts. The U.S. Food and Drug 
Administration (FDA) approved Gardasil-4 for immunization against HPV in males and females aged 
between 9-26 years whereas Cervarix is approved only for females aged between 10-25 years (Ma et 
al., 2010).8 Merck introduced a new HPV vaccine, Gardasil-9, in the U.S. and Europe in 2014 and 2015 
respectively. In addition to the four HPV types covered in Gardasil-4, the new vaccine also provides 
protection against HPV types 31, 33, 45, 52 and 58 (Merck, 2018).  
 
Table 1. Global revenue of Gardasil and Cervarix from 2006-2018. 
 
Gardasil (in 
million US$)* 
Cervarix (in 
million US$)** 
2006 234.8  - 
2007 1,480.6 20.1 
2008 1,402.8 248.75 
2009 1,118.4 306.68 
2010 988 367.84 
2011 1,209 814.66 
2012 1,631 423.9 
2013 1,831 261.44 
2014 1,738 202.96 
2015 1,908 137.28 
2016 2,173 106.92 
2017 2,308 172.86 
2018 3,151 180.78 
* Includes sales of Gardasil-4 and Gardasil-9. From 2016 onwards, only Gardasil-9 was sold in the U.S. (CDC, 
2018b, 2018a). ** Original revenues are in Great Britain Pound (£). We used the exchange rate of the respective 
year on July 2 (MacroTrends, 2019) to calculate the revenue in US$. 
Sources: (Merck, 2008, 2009, 2012, 2015, 2017, 2018) for Gardasil, (GSK, 2008, 2011, 2014, 2017, 2018) 
for Cerverix. 
 
Table 1 shows global revenues of Gardasil and Cervarix between 2006 and 2018. We derive that 
Gardasil has clearly dominated with an average market share of 87% in the period 2007-2018, which 
is the main reason we will focus on Gardasil (in addition to being effective against more HPV types).  
                                                          
8 Both vaccines were found to be safe and immunogenic in clinical trials and were not associated with increased 
risk of autoimmune disorder (Macartney et al., no date; Moreira et al., 2011; Luna et al., 2013; Grimaldi-
Bensouda et al., 2014). In terms of inducing cross reactive antibodies, Cervarix was found to provide significant 
protection against HPV types 31, 33, 45 and 51 (which account to 10-15% of the cervical cancer cases) whereas 
Gardasil-4 only provided cross protection against HPV type 31, 33 and 55 (Schiller et al., 2012; Wheeler et al., 
2012). The geometric mean antibody titres against HPV type 31, 33 and 55 induced by Gardasil-4 and Cervarix 
were comparable (Toft et al., 2014). 
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Vaccination is an integral part of the WHO global strategy to combat HPV infections and related 
diseases (Merck, 2017; UNICEF, 2018). According to WHO recommendations, girls aged 9-14 years 
should receive two doses of Gardasil-4 whereas older age groups receive three doses (UNICEF, 2018). 
It is too early to assess the impact of Gardasil-4 and Cervarix vaccination on prevalence of ICC because 
progress from HPV infection to cancer is very slow. One strategy commonly used to evaluate the 
impact of HPV vaccination is assessing the prevalence of HPV infection or genital warts in the general 
population (McKee et al., 2015). When given at recommended doses, Gardasil-4 has been shown to 
induce antibody protection against HPV types covered by the vaccine for at least 5 years (Garland et 
al., 2007; Choi et al., 2012). In males aged 16-26 years, Gardasil-4 has been shown to provide 90.4% 
efficacy against lesions related to HPV types covered by the vaccine (Giuliano et al., 2011).9 
It is estimated that 70-80% of females in pre-pubertal age have to be vaccinated in order to achieve 
heard immunity (McGraw and Ferrante, 2014). Although HPV vaccination has been introduced in 81 
countries, the high costs of the vaccine and the fact that it requires the delivery of two or three doses 
over a period of 6 months makes it a significant financial and structural burden to most countries in 
the world. For this reason, most LIC and MIC struggle to maintain HPV vaccination without the aid of 
other countries and global organizations such as the WHO, the Global Vaccine Alliance (GAVI), United 
Nations International Children's Emergency Fund (UNICEF) and Pan American Health Organization 
(PAHO) (McKee et al., 2015). 
Despite negotiating much lower prices for LIC and MIC countries, GAVI and other global organizations 
involved in vaccination have repeatedly complained that the prices remain high and this has been one 
of the major factors limiting the expansion of HPV vaccination. In these countries, it has been 
estimated that HPV vaccination has the potential to reduce the lifetime risk of cervical cancer by 31-
60% (Goldie et al., 2008). 
 
2.2 HPV Vaccine Patents 
Academic institutes in the U.S. and Australia first developed the technology employed in the VLP-based 
vaccines in the early 1990s. Merck and GSK then improved on the original invention and performed 
                                                          
9 In Denmark, a study recorded a 67% drop in anogenital warts in females and 50% drop in males vaccinated 
against HPV. Chlamydia infection level remained the same, strongly suggesting that the reduction in HPV 
infection was due to vaccination and not change in sexual behavior (Sandø et al., 2014). In Australia, one of the 
first country to introduce government funded HPV vaccination program, there was a 92% drop in diagnosis of 
genital warts in females under 21 between 2007-2011 (McKee et al., 2015). Another study in Australia has used 
surrogate markers to give an indication of the possible impact of vaccination on cervical cancer. It evaluated a 
cohort of 14,085 unvaccinated and 24,871 vaccinated women within 5 years of the implementation of the 
vaccination program. It found that the subjects in the unvaccinated cohort presented significantly higher 
frequency of histological and cytological high-grade abnormalities (Gertig et al., 2013). 
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the subsequent steps required to bring the vaccine to the market (Padmanabhan et al., 2010). Merck’s 
Gardasil-4, the first VLP based vaccine, was patented in the U.S. in 1998 and introduced in the market 
in 2006 (Castro et al., 2017). Between the first patent approval and 2010, 81 HPV vaccine related 
patents were granted in the U.S. with Merck leading the way with 24 granted patents (Padmanabhan 
et al., 2010).10 
 
Table 2. Patent expiry year of Gardasil-4 and Gardasil-9 in the EU and North America. 
 Gardasil-4 Gardasil-9 
U.S. 2028 2028 
Canada 2020 2025 
EU 2021 2030* 
* The European Union (EU) may give an additional six months of paediatric market exclusivity attached to a 
product’s Supplementary Protection Certificate (SPC) (Merck, 2018).  
Source: (Health Canada, 2018; Merck, 2018). 
 
Typically patents are granted for 20 years but often companies successfully apply for extension up to 
five years (Lakdawalla, 2018). Under the agreement on trade-related aspects of intellectual property 
rights (TRIPS), administered by the World Trade Organization (WTO) and enforced in 1995, member 
countries with an industry capable of manufacturing vaccines must enforce patent protection of 
medicines and biological products (Chandrasekharan et al., 2015). However, under the agreement, the 
least-developed countries (UN, 2018) are not obliged to provide patent protection in general until 
2021, and on medicines (including vaccines) specifically until 2033 (MSF, 2017). 
Brazil, India and China have a large generic pharmaceutical industry supplying 64% of vaccines 
purchase by UNICEF and 43% of vaccines procured by GAVI (Padmanabhan et al., 2010). In addition to 
manufacturing generic vaccines, these countries are also capable of developing HPV vaccines 
themselves (Padmanabhan et al., 2010). A common strategy used in the pharmaceutical industry to 
limit competition from Brazil, India and China is to apply for patents in these countries. There has been 
over 100 HPV vaccine related patent applications with GSK and Merck, the two companies that 
dominate the HPV vaccine market, having by far the highest number of patent applications  
(Chandrasekharan et al., 2015). 
                                                          
10 Given the wide coverage and complexity of patents held by Merck and GSK on HPV vaccine technology, both 
companies cross-licensed their respective intellectual property (IP) holdings to each other in 2005 to enable them 
to have access to the technologies they possess in HPV vaccine R&D and manufacturing (MSF, 2017).  
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There is no centralized database to obtain information about the status of the various patents related 
to a particular vaccine in different countries/regions. For Table 2, we gathered patent expiry years from 
Merck’s annual reports. For simplicity, we focus on patent buyout prices for all country groups and 
total patent values until 2028. 
 
2.3. The Benefit of Patent Buyouts 
WHO has launched a global effort to eliminate cervical cancer promoting introduction of HPV 
vaccination in all countries. The demand is expected to approach 100 million doses per year over the 
next decade. The current suppliers will not be capable to meet the demand meaning that new 
manufacturers will need to enter the market (WHO, 2018).  
In line with the global WHO effort, 48 GAVI-supported countries are expected to introduce multi-age 
cohort HPV vaccination in the coming 10 years (WHO, 2018). The introduction of HPV vaccination in 
China, India and Indonesia adds significantly to global demand. The WHO estimates that from 2023 the 
demand for HPV vaccines will exceed production capacity (GAVI, 2017). 
Under current production capacity it will be challenging to implement gender-neutral and multi-age 
cohort vaccination, as recommended by the WHO, not only because of the limited production capacity 
of the current approved manufacturers but also the high prices of HPV vaccines that are prohibitive to 
GAVI and PAHO supported LIC and MIC as well as in non-supported MIC. In fact, although 81 countries 
have included HPV vaccination in their routine immunization programmes, many LIC and MIC are 
struggling to introduce or maintain the vaccine in their programmes because of its high costs. To date, 
74% of the 81 countries that have introduced the HPV vaccination self-procure the vaccines (WHO, 
2018). 
This suggests the entrance of new manufacturers and vaccines as being crucial to ensure sufficient 
supply and lower HPV vaccine prices, thus increasing economic efficiency. Patent buyout for the 
market leader Gardasil-4 and Gardasil-9 would allow fast entry of competitors.11 
 
 
 
                                                          
11 It will take considerable time until new HPV vaccines from rival companies reach the market. For instance, the 
bivalent vaccines from Innovax and Shanghai Zerun Biotech are in phase III clinical trials whereas the quadrivalent 
HPV vaccine from Serum Institute of India just entered Phase II (WHO, 2018). These vaccines are yet to be tested 
in real world conditions. 
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3. Methodology 
3.1 Patent buyout price 
Our first goal is to estimate the patent buyout price for the vaccine Gardasil in year 𝑇𝑇 = 2020, in 
current (2018) US$.  
To calculate the time path of operating profits, we need estimates for variable and fixed production 
costs, in addition to prices. We assume that the variable production cost per unit (dose) is independent 
of the number of produced doses such that total variable costs are proportional to the units sold. They 
consist of  
- manufacturing costs for materials,  
- user costs of capital (equipment and building),  
- costs for manufacturing labour (manufacturing operators and quality assurance and quality 
control operators), and  
- costs for filling and packaging (staff and material).  
Fixed production costs are calculated for each single facility and consist of  
- overhead labour costs for managing and supervising the manufacturing process of the facility,  
- labour costs for maintenance of the facility and all of its equipment.  
Total fixed costs are the fixed costs of each facility summed up. 
Notably, ex ante costs like R&D expenditures that are sunk at the production stage are not part of the 
fixed production cost.12  
Our data will provide us with recent estimates for the cost components. We use the U.S. price index 
published by the Federal Reserve to deflate all prices and costs to its 2018 value.  
Unlike the number of does sold and consumer prices, we assume that both variable unit costs and 
fixed costs are time-invariant in real terms. We index the country (group) in which Gardasil is sold by 
𝑗𝑗 ∈ {1,2, … , 𝐽𝐽} and denote the time horizon by 𝑇𝑇 (year 2028 in our application). We use information 
about the time paths of the predicted future number of doses sold at the regional level, �𝑦𝑦𝑗𝑗𝑗𝑗�𝑗𝑗=𝑇𝑇
𝑇𝑇 . In 
year t, real operating profits (in 2018 dollars) from country group j are then given by  
𝜋𝜋𝑗𝑗𝑗𝑗 = �𝑝𝑝𝑗𝑗𝑗𝑗 − 𝑐𝑐�𝑦𝑦𝑗𝑗𝑗𝑗,      (1) 
where 𝑐𝑐 denote real variable costs per unit and 𝑝𝑝𝑗𝑗𝑗𝑗  denotes real sales prices in region j and year t. We 
assume that future real sales prices stay at the level we observe last.  
                                                          
12 This also applies to marketing costs.  
 
 
11 
 
Based on (1), we can then estimate the patent buyout price in real dollars, 𝑣𝑣𝑗𝑗, in region j as the 
remaining present discounted value of the patent from period 𝑇𝑇 onwards of the profit stream until the 
patent effectively ends in country group j: 
𝑣𝑣𝑗𝑗(𝑇𝑇) ≔ ∑ 𝜋𝜋𝑗𝑗𝑗𝑗(1+𝑟𝑟)𝑗𝑗−𝑇𝑇𝑇𝑇𝑗𝑗=𝑇𝑇      (2) 
where r is the real annual return to investment in alternative uses (like deposits in banks, equity 
holding, government bonds, etc). We present our estimates for the annual real interest rate r in the 
typical range of 3-7%. 
We will also report global patent buyout prices in year 𝑇𝑇 for the considered regions as a whole: 
𝑉𝑉�𝑇𝑇� ≔ ∑ 𝑣𝑣𝑗𝑗�𝑇𝑇�
𝐽𝐽
𝑗𝑗=1 − 𝐹𝐹   -  (3) 
where F denotes the total real fixed costs of all production facilities. We assume that 𝑐𝑐 and 𝐹𝐹 are the 
same for Gardasil-4 and Gardasil-9.  
 
3.2 Implied Probability of Innovation Under Free Market Entry 
We also aim to estimate the value of an innovation from the perspective of the date introduced in the 
market and compare it with R&D costs. Denote the first full year in which the Gardasil was sold by 𝑠𝑠 =2007, i.e. the total patent value is given by 𝑉𝑉(𝑠𝑠).13 Calculating 𝑉𝑉(𝑠𝑠) requires also the observations for 
the past number of doses and prices for all country groups 𝑗𝑗 (i.e. in years 𝑡𝑡 ∈ {𝑠𝑠, 𝑠𝑠 + 1, … ,𝑇𝑇 − 1}), in 
addition to the information employed to calculate 𝑉𝑉�𝑇𝑇� given in eq. (3).  
If the market for innovations were characterized by free entry, total expected profits would equal zero. 
That is, the expected value of an innovation (accounting for a potentially high risk of R&D failure) would 
equal R&D costs. Formally, the free entry equilibrium condition (zero-profit condition) reads as 
𝜇𝜇 ∙ 𝑉𝑉(𝑠𝑠) = 𝑅𝑅&𝐷𝐷𝑐𝑐𝐷𝐷𝑠𝑠𝑡𝑡𝑠𝑠,      (4) 
where 𝜇𝜇 denotes the probability of a successful innovation. Recall that Gardasil-9 was an improvement 
of Gardasil-4, the first HPV vaccine approved by the FDA (Tomljenovic and Shaw, 2012). Gardasil-4 and 
Gardasil-9 are typically not sold in parallel within the same region. Thus, we sum up both the profits 
from both Gardasil-4 and Gardasil-9 and add up the R&D costs for both when applying eq. (4). Given 
our estimates of R&D costs and the innovation value, we obtain 𝜇𝜇 = 𝑅𝑅&𝐷𝐷 𝑐𝑐𝑐𝑐𝑐𝑐𝑗𝑗𝑐𝑐
𝑉𝑉(𝑐𝑐)  as the theoretical 
probability of a successful innovation under the free entry assumption. If 𝜇𝜇 were deemed too low, then 
we would have indication of excessive market power. 
                                                          
13 We neglect sales in year 2006, as Gardasil-4 was only sold in the U.S. after its approval in September 2006 and 
we do not have price information.  
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4. Data for Operating Profit Estimates 
4.1. HPV Vaccine Prices 
When Gardasil was first released in the U.S. market it was sold at US$ 96.75 per dose to Centers for 
Disease Control (CDC) funded programs and US$ 120.5 per dose to the private sector making it the 
most expensive vaccine at the time (Table 3) (Nguyen et al., 2011; CDC, 2018a). In 2018, it was sold at 
a price of US$144.2 and US$ 217.1 to CDC and the private sector respectively (CDC, 2018a). Since the 
data about the number of doses sold to CDC and the private sector is not available we assume in Table 
3 that each corresponds to 50% of the total doses sold and calculate the U.S. price as the simple mean 
of the price charged to the two groups. Since we have prices from various years, we converted all 
prices to 2018 US$, using the U.S. consumer price index (Federal Reserve Bank, 2018).14  
 
Table 3. Gardasil prices* per dose in the U.S. from 2007-2018. 
Year CDC (in current US$) 
Private 
Sector (in 
current US$) 
Average 
price (in 
current US$) 
Price in 2018 
US$** 
2007 96.75 120.50 108.63 131.55 
2008 100.59 125.29 112.94 131.72 
2009 105.58 130.27 117.93 138.03 
2010 108.72 130.27 119.50 137.61 
2011 95.75 130.27 113.01 126.16 
2012 98.60 135.45 117.03 127.99 
2013 107.16 135.45 121.30 130.76 
2014 121.03 141.38 131.21 139.17 
2015 121.03 160.17 140.60 148.96 
2016 119.04 193.63 156.34 163.57 
2017 116.22 204.87 160.55 164.47 
2018 144.18 217.11 180.64 180.64 
* In 2016, Gardasil-4 was replaced by Gardasil-9. ** Deflated by the price index (PI) as given in Table B.1. 
Source: (CDC, 2018a) and own calculations. 
 
Globally the prices of HPV vaccines vary greatly depending on procurement agreement and countries’ 
income (UNICEF, 2018). Merck and GSK have agreements with organizations such as GAVI (mediates 
purchase of vaccine to developing countries in Africa and Asia) and PAHO (mediates vaccine purchase 
to LIC and MIC in South and Central America) (GAVI, 2018; PAHO, 2019) . Table 4 displays the median 
price per dose for Gardasil-4 and Gardasil-9 in the year 2016 and the one in 2018 US$ for various 
                                                          
14 See Supplementary Material (Table B.1). 
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(groups of) countries. We see that although median prices are much higher in HIC, the vaccines are 
particularly expensive in China.  
 
Table 4. Prices of Gardasil-4 and Gardasil-9 in different countries and country groups (median prices 
within the groups of HIC and MIC), excluding the U.S, 2016. 
 2016, in curent US$ In 2018 US$*  
Gardasil-4 Gardasil-9 Gardasil-4 Gardasil-9 
HIC (excl. the U.S.) 44.12 91.00 45.96 94.79 
MIC 19.70  20.52  
GAVI 4.50  4.69  
India 6.90  7.19  
Indonesia 14.76  15.38  
China 120.00 153.00 125.00 159.38 
* Prices for 2016 are deflated by PI=0.96 (Table B.1). 
Sources: HIC, MIC, GAVI, PAHO (UNICEF, 2018); India (Sabeena et al., 2018); Indonesia (Setiawan et al., 
2016); China (Yin, 2017; Cheung and Zhang, 2018) and own calculations.  
 
4.2 Number of Doses Sold 
To calculate operating profits for a year t as given in eq. (1), we also need an estimate the number of 
doses 𝑦𝑦𝑗𝑗𝑗𝑗 in each country group j. Currently there are no publicly available data on the number of doses 
of Gardasil sold globally. GAVI (2017), through its own databases and interviews with stakeholders (i.e. 
national vaccination programme managers, industry leaders and experts), estimated the number of 
HPV doses sold between 2006-2017 by country group and forecasted quantities for 2018-2027. 
Unfortunately, for the past, only the total number of doses per year for HIC as a whole is available, 
which is problematic as we see by comparing Table 3 and 4 that prices are much higher in the U.S. 
Thus, one challenge is to derive the breakdown of the total number of units between the U.S. and 
other HIC for the period 2007-2017 (recall that we aim to calculate the patent value since 2007).  
We infer these figures as follows: we use the available Gardasil revenue information for the U.S. 
(Merck, 2019) in 2015-2017 to calculate in Table 5a its average market share during that period. It 
amounts to 76.46%. Then we assume U.S. the market share was the same also in 2007-2014 and infer 
the Gardasil-4 sales revenue for the U.S. market in this period by using global revenues as given in 
Table 1. Finally, we divide the U.S. sales revenues by the information on the nominal (average) price in 
Table 3. 
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Table 5a. U.S. market share, 2015-2017. 
Year U.S. revenue (in million US$) 
Total revenue (in 
million US$) U.S. market share (%) 
2015 1,520 1,908 79.66 
2016 1,780 2,173 81.91 
2017 1,565 2,308 67.81 
Average U.S. market share 76.46 
Source: (Merck, 2019) 
 
Table 5b. Total Gardasil sales revenues, its estimated composition (U.S. vs. non-U.S.) and estimated 
number of doses sold in the U.S., 2007-2017. 
 Revenue (in million US$) U.S. 
Year U.S.* Non-U.S. *  Total Nominal U.S. price/dose** 
Number of doses sold in the 
U.S. (in millions) 
2007 1,132.07 348.53 1,480.60 108.63 10.42 
2008 1,072.58 330.22 1,402.80 112.94 9.50 
2009 855.13 263.27 1,118.40 117.93 7.25 
2010 755.42 232.58 988 119.5 6.32 
2011 924.40 284.60 1,209 113.01 8.18 
2012 1,247.06 383.94 1,631 117.03 10.66 
2013 1,399.98 431.02 1,831 121.30 11.54 
2014 1,328.87 409.13 1,738 131.21 10.13 
2015 1,520 388 1,908 140.60 10.81 
2016 1,780 393 2,173 156.34 11.39 
2017 1,565 743 2,308 160.55 9.75 
* For 2007-2014 we assumed the U.S. (non-U.S.) market share corresponds to 76.46% (23.54%) of the global 
Gardasil revenue market, as calculated in Table 5a, using the figure for total revenues. ** The column restates 
the average price from Table 3. 
Source: (GAVI, 2017) and own calculations. 
 
Table 5c. Nominal prices and number of doses in HIC excluding the U.S., 2007-2009. 
Year Revenue  
(in million US$) 
Nominal price/dose in 
other HIC (in US$)* 
Number of doses sold in 
other HIC (in millions)** 
2007 348.53 37.95 9.18 
2008 330.22 39.41 8.38 
2009 263.27 39.27 6.70 
* Calculated from Table 4 and PI in Table B.1. ** We used the revenue information for non-U.S. countries from 
Table 5b. 
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Table 5b displays the number of Gardasil doses sold in the U.S. derived by that procedure (in addition 
to sales revenues derived as intermediate steps). Table 5c uses the breakdown of revenues together 
with the information on prices in Table 4 to infer the number of units sold in 2007-2009 in HIC other 
than the U.S., using the information by Merck that Gardasil has only been sold in HIC in that period. 
The price estimate is constructed by multiplying the real Gardasil-4 price of 45.96 US$ (in 2018 US$) 
shown in Table 4 by its PI in the respective year from Table B.1. 
 
Table 6a. Number of Gardasil doses sold in different countries and country groups between 2010-
2017 and forecasted quantities until 2027. 
Year 
Number of doses (in millions) 
HIC 
total U.S.** Other 
HIC*** 
MIC GAVI India/Indonesia China 
Total 
2010 15.66 6.32 9.34 6.09 0 0 0 21.75 
2011 20.88 8.18 12.70 11.31 0 0 0 32.19 
2012 18.27 10.66 7.61 13.92 0 0 0 32.19 
2013 17.4 11.54 5.86 13.92 0.87 0 0 32.19 
2014 15.23 10.13 5.10 11.31 0.87 0 0 27.41 
2015 14.79 10.81 3.98 9.57 1.74 0 0 26.10 
2016 15.66 11.39 4.27 9.57 2.61 0.87 0 28.71 
2017 15.66 9.75 5.91 9.57 1.74 0.87 0 27.84 
Subtotal 133.5 78.77 54.77 85.26 7.83 1.74 0 228.38 
2018* 14.79 8.84 5.95 10.44 5.22 0.87 0 31.32 
2019* 15.23 9.10 6.12 12.18 23.49 0.87 0 51.77 
2020* 16.53 9.88 6.65 13.05 34.8 0.87 0 65.25 
2021* 15.66 9.36 6.30 13.05 26.97 13.92 0 69.60 
2022* 14.79 8.84 5.95 13.05 28.71 25.23 0.87 82.65 
2023* 13.92 8.32 5.60 13.05 31.32 23.49 2.61 84.39 
2024* 13.05 7.80 5.25 13.92 21.75 24.36 3.48 76.56 
2025* 12.18 7.28 4.90 14.79 27.84 21.75 3.48 80.04 
2026* 12.18 7.28 4.90 14.79 26.1 20.01 4.35 77.43 
2027* 12.18 7.28 4.90 14.79 25.23 18.27 6.09 76.56 
Subtotal 140.5 84.02 56.48 133.11 251.43 149.64 20.88 695.57 
* Assuming that the number doses sold in the U.S. from 2018-2027 corresponds to 59.8% of the total number of 
doses sold in HIC markets (see Table 6b). ** For 2010-2017, see Table 5b. *** Implied by subtracting the number 
for HIC total and the U.S. 
Source: (GAVI, 2017) and own calculations. 
 
For the period 2010-2017 we can again use our estimates for the number of doses in the U.S. to infer 
those of other HIC. The results are given in Table 6a. For the period 2018-2027, we assume that the 
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share among HIC of the number of doses sold in the U.S. from 2018-2027 corresponds to its average 
share in period 2010-2017. According to Table 6b, on average, 59.8% of the total number of doses sold 
in HIC markets are sold in the U.S. 
 
Table 6b. U.S. share of total number of doses sold in HIC, 2010-2017. 
Year Number of doses sold in all HIC (in millions) 
Number of doses sold 
in U.S. (in millions)* 
U.S. market 
share (in %) 
2010 15.66 6.32 40.4 
2011 20.88 8.18 39.2 
2012 18.27 10.66 58.3 
2013 17.4 11.54 66.3 
2014 15.23 10.13 66.5 
2015 14.79 10.81 73.1 
2016 15.66 11.39 72.7 
2017 15.66 9.75 62.2 
Average U.S. market share (in %) 59.8 
* See Table 5b. 
Source: (GAVI, 2017) and own calculations. 
 
For the other regions, the past and forecasted number of Gardasil doses sold have been directly 
provided (GAVI, 2017). They are also displayed in Table 6a. The biggest factor that will drive the 
increase in global demand of HPV vaccine is the introduction of HPV vaccination in China, India and 
Indonesia (three of the four most populous countries in the world). These countries are expected to 
represent approximately 1/3 of the global market by 2030 (GAVI, 2017; WHO, 2018). China, India and 
Indonesia delayed the introduction of Gardasil-4 and Gardasil-9 in their public health programmes due 
to concerns over safety, effectiveness of the vaccine across different age groups and price. China 
approved the introduction of Gardasil-4 and Gardasil-9 in 2017 and 2018 respectively, Indonesia 
introduced Gardasil-4 in late 2015 and India did so in 2018 (Kosen et al., 2017; Das, 2018; Hongyu, 
2018; Sagonowsky, 2018). 
 
4.3 Variable Costs for Manufacturing Gardasil 
As outlined in section 3, we distinguish variable and fixed manufacturing costs.15 Variable costs consist 
of annual costs for labour, per-batch costs for raw materials, filling and packaging the vaccine, and 
capital costs. Fixed costs include management and supervisor overhead costs and fixed costs required 
                                                          
15 In line with our methodology, most studies do not include the costs of R&D, marketing, general administration 
and legal services in the estimation of manufacturing costs (Mahoney, 1990; Smith et al., 2011; Mahoney et al., 
2012). 
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to fulfil ‘Good Manufacturing Practices’ (GMP) guidelines, i.e. “factory and administrative overhead” 
(Clendinen et al., 2016).  
Annualized capital costs consist of building and equipment costs, where equipment represents around 
one-third of these costs. We follow the procedure to assume a 5% real (no-inflation) discount rate, 10 
years of useful life for the equipment and 25 years of useful life for the building (Mahoney et al., 2012; 
Clendinen et al., 2016). For Gardasil-4, as shown in Table 7a, one quarter of the US$1 billion (in 2014 
US$) spent by Merck in building its manufacturing complex in Durham (North Carolina), was used as 
the high estimate for total variable capital costs; and a 40% discount, or $150 million for the low 
estimate (Clendinen et al., 2016). Based on the total number of doses between 2010-2017 derived in 
Table 6a, Table 7b displays the number of doses of Gardasil-4 that can be manufactured annually with 
the total investment for building and equipment shown in Table 7a.  
 
Table 7a. Total capital (building and equipment) costs for Gardasil-4 (in 2014 US$). 
  Low Estimate High Estimate 
Investment (in million US$) 
Building cost 100 166.7 
Equipment cost 50 83.3 
Total investment in building and equipment 150 250 
Cost of capital (in million US$) 
Annualized capital cost - Building*  6.8 11.3 
Annualized capital cost - Equipment* 6.2 10.3 
Total annualized capital cost* 13 21.6 
* Assuming 5% real (no inflation) discount rate; useful life 10 years for equipment and 25 years for building; 
range of costs shown to reflect uncertainty in estimates.  
Source: (Clendinen et al., 2016). 
 
Table 7b. Number of doses of Gardasil-4 manufactured. 
    Number of doses (in millions) 
A Total number of doses between 2010-2017* 228.375 
B Average number of doses per year 28.546875 
* See Table 6a. 
 
Table 7c uses the information in Tables 7a and 7b to calculate the range of variable capital costs per 
one million doses of Gardasil-4. 
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Table 7c. Estimated variable capital costs (per year) for manufacturing 1 million doses of Gardasil-4. 
 Low estimate (in US$) 
High estimate 
(in US$) 
Variable building cost (annualised capital cost/B) 238,204.71 395,840.18 
Variable equipment cost (annualised capital cost/B) 217,186.64 360,810.07 
Total variable capital cost for one million doses (in 2014 US$) 455,391.35 756,650.25 
Total (in 2018 US$)* 428,067.87 711,251.24 
* Deflated by PI from Table B.1. 
Source: Own calculations based on Table 7a and 7b. 
 
Table 8. Estimated cost of materials for producing 1 million doses of Gardasil-4. 
Materials (units)* 
Package 
sold by life 
science 
companies 
Price 
per 
package 
(US$) 
Number of 
packages 
needed per 
million 
doses 
Price for 1 
million 
doses (US$) 
Yeast Media (kg) 0.02 100 7.11 35,532.47 
Yeast Extract (kg) 1.00 300 88.83 26,649.35 
Soy Protein (kg) 25.00 2,600 44.42 4,619.22 
Magnesium Chloride (kg) 5.00 150 0.78 23.38 
Thimerosal (g) 500.00 2,000 18.17 72.67 
Glucose (kg) 2.50 250 88.83 8,883.12 
Sodium Hydroxide (kg) 5.00 200 4.04 161.45 
Galactose (kg) 5.00 700 177.66 24,872.73 
PS--80 (kg) 25.00 360 10.09 145.37 
Sodium Chloride (kg) 50.00 550 646.04 7,106.49 
DTT (g) 100.00 1,000 38.96 389.61 
Benzonase (ku) 25.00 180 299.81 2,158.60 
MOPS (kg) 5.00 2,000 1.95 779.22 
Ammonium sulfate (kg) 5.00 290 9.81 569.00 
Microfiltration filters 1.00 10,000 0.10 974.03 
Hollow--fiber membranes 1.00 9,000 0.10 876.62 
PVDF—Millipore200 (3pk=3000L) 1.00 850 0.10 82.79 
Poros 50HS beads 20x3ft (L) 10.00 22,500 34.77 78,222.56 
Filling and packaging 310,000.00 
High Estimate – Total listed retail prices (in 2013 US$) 502,118.67 
High Estimate – Total listed retail prices (in 2018 US$)** 539,912.55 
Low Estimate – Discounted at 40% (in 2018 US$)** 323,947.53 
** Deflated by PI from Table B.1. 
Source: (Clendinen et al., 2016) and own calculations. 
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Merck’s Gardasil-4 is produced from a combination of non-infectious and non-oncogenic VLPs that 
mimic the virion structure of the infectious particles of common HPV strains. It contains four VLPs of 
HPV type 6, 11, 16, and 18 each absorbed onto aluminium hydroxyphosphate sulphate (AAHS) 
adjuvant. All steps of the purification of L1 proteins are done individually for each protein (Clendinen 
et al., 2016). 
The manufacturing process has four steps: cultivation, extraction, purification type-specific VLPs from 
L1-recombinant producer cells, filling and packaging (Clendinen et al., 2016). Table 8 displays the costs 
of materials (in 2013 US$) for one million doses of Gardasil-4 (the number of doses sold until May 
2013). The materials are based on published papers from Merck on how the L1 proteins are produced 
and their costs are taken from the U.S. based life science and technology companies list prices in 2013. 
The variable materials cost for filling and packaging is US$ 310,000 for 1 million doses, being composed 
of the wholesale cost of the vial, cap and stopper (for single-dose packaging) at US$ 0.21 per dose plus 
secondary packaging materials at US$ 0.10 per dose (Clendinen et al., 2016). 
According to (Clendinen et al., 2016), it takes 152 personnel across different functions (management, 
manufacturing, inspection and quality assurance) to manufacture two sets of batches or up to 30.8 
million doses of Gardasil-4 in one year. Table 9 presents the range of salaries (low and high) per one 
million doses paid to operators involved in manufacturing, quality assurance and control plus staff 
costs for filling and packaging. 
 
Table 9. Variable labour cost for producing 1 million doses of Gardasil-4.  
Number of 
employees 
Personnel 
Salary costs per 
employee for one 
million doses (US$) 
Total salary costs (US$) 
per million doses 
Type Low High Low High 
60 Manufacturing Operators 1,623.38 2,272.73 97,402.60 136,363.64 
47 
Quality Assurance and 
Quality Control 
Operators 
1,623.38 2,272.73 76,298.70 106,818.18 
34 Fill/Pack Staff 1,623.38 2,272.73 55,194.81 77,272.73 
Total (in 2014 US$) 228,896.10 320,454.55 
Total (in 2018 US$)* 243,506.49 340,909.09 
** Deflated by PI from Table B.1. 
Source: (Clendinen et al., 2016) and own calculations. 
 
In Table 10 we arrive at two estimates (low and high) of the total variable costs per dose, to 
manufacture one million doses of Gardasil, based on Tables 7c, 8 and 9. It is interesting to compare 
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them to prices as given in Tables 3 and 4 for the U.S. and other (groups of) countries. For instance, in 
2016, even the high estimate would suggest a price-cost margin (mark-up factor) around 100 for the 
U.S. and China in the year 2016 and above 12 in MIC.  
 
Table 10. Total variable costs for manufacturing 1 million Gardasil doses (in 2018 US$). 
 Low estimate High estimate 
Material costs (per million doses) 323,947.53 539,912.55 
Variable labour costs (per million doses) 243,506.49 340,909.09 
Variable capital costs (per million doses) 428,067.87 711,251.24 
Total variable costs per million doses 995,521.89 1,592,072.88 
Total variable costs per dose 1.00 1.59 
Source: Own calculations based on Tables 7c, 8 and 9. 
 
5. Operating Profits, Fixed Costs and Patent Value 
5.1. Operating Profits  
Table 11 displays the profits in 2018 US$ by using eq. (1).16 The data used to calculate profits were 
obtained from the estimations above: vaccine prices, 𝑝𝑝𝑗𝑗𝑗𝑗, in the U.S. (Table 3) and other country groups 
(Table 4), number of doses sold, 𝑦𝑦𝑗𝑗𝑗𝑗 (Table 6a) and variable costs, 𝑐𝑐 (Table 10). The estimations suggest 
a future reduction of the U.S. market share caused by the forecasted increasing demand for the vaccine 
in other regions particularly in China, India and Indonesia. Future profits tend to increase until 2027.  
 
Table 11. Estimated past and future Gardasil operating profits in different countries and country 
groups, applying eq. (1). All values in million 2018 US$. 
a) 2007-2009  
 
Estimation 
Year (in million 2018 US$) 
 2007 2008 2009 
U.S. 
High (US$) 1,360.59 1,241.45 993.64 
Low (US$) 1,354.45 1,235.85 989.36 
Other HIC 
High (US$) 412.90 376.74 301.43 
Low (US$) 407.48 371.80 297.48 
Total profit 
per year 
High (US$) 1,773.49 1,618.19 1,295.07 
Low (US$) 1,761.93 1,607.64 1,286.84 
                                                          
16 Calculations are displayed in Table B.2 of the Supplementary Material. 
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b) 2010-2019 
 
Estimation 
Year (in million 2018 US$) 
 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 
U.S. 
High 863.61 1,023.76 1,353.26 1,497.51 1,399.41 1,599.55 1,850.93 1,593.48 1,588.83 1,635.56 
Low 859.88 1,018.93 1,346.97 1,490.71 1,393.44 1,593.17 1,844.22 1,587.73 1,583.62 1,630.19 
Other HIC 
High 419.83 570.98 342.30 263.41 229.14 178.90 192.16 265.79 267.30 275.17 
Low 414.32 563.49 337.80 259.95 226.14 176.55 189.64 262.30 263.80 271.55 
MIC 
High 118.88 220.78 271.73 271.73 220.78 186.81 186.81 186.81 203.80 237.76 
Low 115.29 214.11 263.52 263.52 214.11 181.17 181.17 181.17 197.64 230.58 
GAVI 
High       3.21 3.21 6.42 9.62 6.42 19.25 86.62 
Low       2.69 2.69 5.39 8.08 5.39 16.17 72.76 
Indonesia/ 
India 
High             8.94 8.94 8.94 8.94 
Low             8.43 8.43 8.43 8.43 
Profit per 
year (in 
million 
US$) 
High  1,402.32 1,815.52 1,967.28 2,035.86 1,852.54 1,971.68 2,248.48 2,061.45 2,088.13 2,244.06 
Low  1,389.49 1,796.53 1,948.29 2,016.87 1,836.38 1,956.28 2,231.54 2,045.02 2,069.65 2,213.52 
c) 2020-2027 
 
Estimation 
Year (in million 2018 US$) 
 2020 2021 2022 2023 2024 2025 2026 2027 
U.S. 
High 1,350.38 1,172.05 1,123.15 1,080.10 1,078.26 1,077.67 1,184.07 1,190.63 
Low 1,344.54 1,166.53 1,117.94 1,075.19 1,073.66 1,073.38 1,179.77 1,186.33 
Other HIC 
High 298.75 283.03 267.30 251.58 235.86 220.13 220.13 220.13 
Low 294.83 279.31 263.80 248.28 232.76 217.24 217.24 217.24 
MIC 
High 254.75 254.75 254.75 254.75 271.73 288.71 288.71 288.71 
Low 247.05 247.05 247.05 247.05 263.52 279.99 279.99 279.99 
GAVI 
High 128.33 99.45 105.87 115.49 80.20 102.66 96.24 93.04 
Low 107.79 83.54 88.93 97.01 67.37 86.23 80.84 78.15 
Indonesia/ 
India 
High 8.94 143.12 259.40 241.51 250.45 223.62 205.73 187.84 
Low 8.43 134.90 244.51 227.65 236.08 210.78 193.92 177.06 
China 
High     137.79 413.36 551.15 551.15 688.93 964.50 
Low     137.27 411.82 549.09 549.09 686.36 960.91 
Profit per 
year (in 
million 
US$) 
High  2,041.14 1,952.39 2,148.26 2,356.79 2,467.65 2,463.94 2,683.81 2,944.85 
Low  2,002.65 1,911.33 2,099.49 2,307.00 2,422.48 2,416.72 2,638.13 2,899.68 
Source: Own calculations based on Tables 3, 4, 6a, 10. 
 
5.2. Present Discounted Value of Operating Profits  
Based on the profit information in Table 11, we now apply eq. (2) to calculate the future (2020-2028) 
and total (2007-2028) present discounted value (PDV) of operating profits. We assume that operating 
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profits in 2028 are the same as 2027. Table 12 presents the results for three discount rates, r=0.03, 
r=0.05 and r=0.07, using the low and high cost estimates. We estimate future operating profits 
between US$ 16,25 – 19,35 billion, and total operating profits of US$ 22,86 – 33,45 billion. 
Table 12. Estimated PDV of operating profits between 2020-2028 and 2007-2028, applying eq. (2). 
 
 
Source: Own calculations based on Table 11 and assumption that 2028 values are the same as 2027. 
   In million 2018 US$ 
 Discount rate (r) Estimation 2020-2028 2007-2028 
U.S. 
0.03 High 9,308.62 21,257.71 Low 9,261.67 21,161.71 
0.05 High 8,671.40 17,890.32 Low 8,626.94 17,807.78 
0.07 High 8,108.78 15,294.15 Low 8,066.53 15,222.02 
Other HIC 
0.03 High 1,979.46 4,871.73 Low 1,946.13 4,799.74 
0.05 High 1,851.48 4,197.65 Low 1,819.82 4,134.51 
0.07 High 1,738.05 3,674.54 Low 1,707.89 3,618.27 
MIC 
0.03 High 2,155.00 3,167.92 Low 2,080.49 3,072.18 
0.05 High 1,999.03 2,538.24 Low 1,929.24 2,461.52 
0.07 High 1,861.39 2,064.21 Low 1,795.75 2,001.83 
GAVI 
0.03 High 796.35 655.46 Low 650.38 550.59 
0.05 High 742.64 484.96 Low 605.26 407.37 
0.07 High 695.09 362.17 Low 565.33 304.22 
Indonesia/India 
0.03 High 1,495.95 1,049.12 Low 1,403.87 988.92 
0.05 High 1,380.28 755.72 Low 1,294.83 712.36 
0.07 High 1,277.32 548.91 Low 1,197.78 517.41 
China 
0.03 High 3,618.69 2,448.60 Low 3,605.21 2,439.48 
0.05 High 3,252.32 1,707.46 Low 3,240.20 1,701.10 
0.07 High 2,931.55 1,200.18 Low 2,920.63 1,195.71 
Total operating profits 
0.03 High 19,354.08 33,450.55 Low 18,947.75 33,012.61 
0.05 High 17,897.14 27,574.36 Low 17,516.30 27,224.64 
0.07 High 16,612.17 23,144.17 Low 16,253.91 22,859.46 
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5.3. Fixed Costs 
Gardasil is currently manufactured in a dedicated facility built in Durham, North Carolina (Clendinen 
et al., 2016). Recently, Merck announced an expansion of the North Carolina facility and build a new 
one, the two facilities are expected to be fully operational from 2022 (Shamp, 2019). Since all factories 
are based in the U.S., we assume that the costs are the same in these additional factories and multiply 
the current fixed costs by three to obtain an estimate on total fixed costs from 2022 onwards.  
 
Table 13a. Total fixed costs per year.  
  Personnel Annual Salary (US$) Total Costs (US$) 
Number Type Low High Low High 
1 Director 150,000 200,000 150,000 200,000 
3 Managers 100,000 150,000 300,000 450,000 
7 Supervisors 70,000 100,000 490,000 700,000 
Subtotal (in 2014 US$) 940,000.00 1,350,000.00 
Subtotal (in 2018 US$) 1,000,000.00 1,436,170.21 
Factory and administrative overhead (in 2018 US$)* 7,740,365.58 11,962,632.65 
Total fixed costs per factory per year (in 2014 US$) 9,680,365.58 14,748,802.86 
Total fixed costs per factory per year (in 2018 US$) (2007-2021) 10,298,261.25 15,690,215.81 
Total fixed costs in 3 factories per year (from 2022)  30,894,783.75 47,070,647.43 
* Derived in Table 13b. 
Source: (Clendinen et al., 2016) and own calculations. 
 
Table 13b. Low and high estimate for the factory and administrative overhead. 
  
Low estimate 
(in 2018 US$) 
High estimate 
(in 2018 US$) 
Annual personnel cost  
Fixed* 1,000,000.00 1,436,170.21 
Variable (cost of 1 million x 28.55)* 6,952,110.39 9,732,954.55 
Cost of materials (cost of 1 million x 28.55)* 9,248,702.01 15,414,503.35 
Total 17,200,812.40 26,583,628.11 
Factory and Administrative Overhead Costs (45% costs of 
personnel and material) 7,740,365.58 11,962,632.65 
* Fixed labour costs are taken from Table 13a. ** For variable costs of labour and materials per one million doses, 
see Table 10. These are multiplied by the average number of doses sold per year between 2010-2017 (i.e. 28.55 
million, according to Table 6a).  
Source: Own calculations based on Table 11. 
 
Table 13a lists the estimated annual fixed labour costs which correspond to salaries paid to the 
director, managers and supervisors for this factory. We also include “factory and administrative 
overhead” costs encompassing all the costs of maintenance of the facility and the equipment according 
to GMP guidelines (electricity, heating, cooling and operation of the machinery). As a convention 
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“factory and administrative overhead” correspond to 45% of the total cost for personnel and material 
(Clendinen et al., 2016). They are calculated in Table 13b 
 
5.4. Estimated Global Value of Gardasil Patents and the Patent Buyout Price in 2020 
Using eq. (3), Table 14 shows the present discounted value of the patent from 2007-2028 and 2020-
2028 (median patent expiring year), based on the information in Table 12 and 13a on operating profits 
and fixed costs, respectively. The global patent buyout in 2020, considering the different real annual 
return to investment in alternative uses (r) and assuming patent expiry in 2028, vary between US$ 
15,327.48 – 18,320.83 million (in 2018 US$). We did not include the operating profits for GAVI 
supported countries because these are not obliged to provide patent protection on vaccines until 2033 
(MSF, 2017). We include those profits to derive the total patent value for 2007-2028 that we employ 
further in section 6. It amounts to US$ 22,294.26 – 33,079.75 million (in 2018 US$).  
 
Table 14. Estimated global patent buyout in 2020 and total value of the Gardasil innovation, applying 
eq. (3).  
  2020-2028 (in million 2018 US$) 2007-2028 (in million 2018 US$) 
Discount rate (r) Estimate Operating profits* 
Fixed 
costs  
Patent 
buyout 
price 
Operating 
profits 
Fixed 
costs 
Patent 
value 
0.03 
High 18,557.73 236.90 18,320.83 33,450.55 370.80 33,079.75 
Low 18,297.37 361.10 17,936.27 33,012.61 565.20 32,447.41 
0.05 
High 17,154.50 236.90 16,917.60 27,574.36 370.80 27,203.56 
Low 16,911.04 361.10 16,549.94 27,224.64 565.20 26,659.44 
0.07 
High 15,917.08 236.90 15,680.18 23,144.17 370.80 22,773.37 
Low 15,688.58 361.10 15,327.48 22,859.46 565.20 22,294.26 
*We did not include operating profits from GAVI supported countries because these are not obliged to provide 
patent protection on vaccines until 2033. 
Source: Own calculations based on Table 12 and Table 13a. 
 
6. R&D Cost Estimates for Gardasil and Its Relation to the Patent Value 
This section relates the total value of the Gardasil patents in Table 14 to its R&D costs. To calculate the 
R&D costs, we added the costs of clinical trials (phase I to III)17. We did not include the costs of pre-
                                                          
17 In phase I of clinical trials the vaccine is tested in a small number of healthy individual to identify the best route 
to administer the vaccine, frequency and dose escalation, the maximum tolerated dose (MTD) and side effects 
(Mahan, 2014). The main aim of phase II is to demonstrate the efficacy and immunogenicity of the vaccine 
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clinical development because it was mainly performed by academic institutions (Padmanabhan et al., 
2010). 
To estimate the costs of each clinical trial we performed literature review coupled with a search in 
www.clinicaltrial.gov to identify the Gardasil related clinical trial sponsored by Merck. An earlier study 
estimated that the cost per subject (set-up, recruitment, administration and support) is between US$ 
100-400 in phase I, US$ 300–400 in phase II and US$ 2000-3000 in phase III (inflation-adjusted costs in 
2008 US$). We restate the information in Table 15 (Light et al., 2009). To calculate how much was 
spent per clinical trial the number of subjects involved in the study was multiplied by the estimation 
of the cost per subject.  
 
Table 15. Cost per subject per clinical trial phase 
 
Cost per subject 
(in 2008 US$) 
Cost per subject 
(in 2018 US$)* 
 Low High Low High 
Phase I 100.00 400.00 116.28 465.12 
Phase II 300.00 400.00 348.84 465.12 
Phase III 2,000.00 3,000.00 2,325.58 3,488.37 
* Deflated by PI from Table B.1. 
Source: (Light et al., 2009). 
 
In addition to subject related costs, there are site (recruitment and retention of subjects, 
administrative and site monitoring) and study costs (data collection and management, institutional 
review board (IRB) approvals and amendments, source data verification, overheads and other costs). 
According to a previous study (Sertkaya et al., 2016), the site costs are US$ 682,284 for phase I, US$ 
3,791,310 for phase II and US$ 5,647,045 for phase III. The study costs for phase I is US$ 2,058,396, 
US$ 6,273,284 for phase II and US$9,063,763 for phase III. The data represent the mean costs from 
2004-2012 and not adjusted for inflation. In Table 16, we thus used the PI from the median year (2008) 
to calculate the corresponding 2018 costs. Tables A.1 and A.2 in Appendix list the conducted studies 
for phases I to III testing Gardasil-4 and Gardasil-9, respectively. To calculate how much was spent on 
site and study costs per clinical trial phase, we multiply the number of studies on each phase by the 
estimated site and study costs of the corresponding phase. 
 
                                                          
candidate in a larger group (Mahan, 2014). In phase III the safety, immunogenicity and efficacy of the final dosage 
of the vaccine is tested in thousands of subjects and is tested against a placebo and/or another vaccine in the 
market (Lakdawalla, 2018). 
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Table 16. Site and study costs estimates for each phase of the clinical trial  
  Phase I Phase II Phase III 
Site costs 
Recruitment 51,904.00 233,729.00 395,182.00 
Site retention 193,615.00 1,127,005.00 1,305,361.00 
Administrative staff 237,869.00 1,347,390.00 2,321,628.00 
Monitoring 198,896.00 1,083,186.00 1,624,874.00 
Total (in 2008 US$) 682,284.00 3,791,310.00 5,647,045.00 
Total (in 2018 US$) 793,353.49 4,408,500.00 6,566,331.40 
Study costs 
Data management 50,331.00 59,934.00 39,047.00 
IRB approvals 11,962.00 60,188.00 114,118.00 
IRB amendments 1,094.00 1,698.00 1,919.00 
Source data verification 326,437.00 406,038.00 400,173.00 
Overheads 528,685.00 1,741,811.00 2,541,313.00 
Other costs 1,139,887.00 4,003,615.00 5,967,193.00 
Total (in 2008 US$) 2,058,396.00 6,273,284.00 9,063,763.00 
Total (in 2018 US$)* 2,393,483.72 7,294,516.28 10,539,259.30 
* Deflated by PI=0.86 for year 2008 from Table B.1. 
Source: (Sertkaya et al., 2016) 
 
Using the information of Tables 15 and 16 jointly with the information on clinical trials in Table A.1, we 
estimate the R&D costs for all clinical phases for Gardasil-4 was between US$ 539,797,626 – 
594,410,998, as shown in Table 17. Moreover, using Tables 15 and 16 jointly with the information on 
clinical trials in Table A.2, Table 17 displays the analogous R&D costs for Gardasil-9 in the range of US$ 
419,175,907 – 458,228,307.  
These R&D costs do not include capital costs that, unfortunately, are not available. We thus add a 
generous value of 15% to the costs estimated in Table 17 in order not to underestimate total R&D 
costs. As displayed in Table 18, the estimated total R&D costs of both vaccines is between US$ 
1,102,822,520 – 1,210,547,032. 
We now put our low and high estimate for total R&D costs in relation to the low and high estimate of 
the total innovation value, applying eq. (4). This provides us with a range for the theoretical innovation 
probability (𝜇𝜇) under free entry into R&D. The lower bound is found by dividing the low estimate for 
R&D costs from Table 18 (US$ 1,102.82 million) and the high estimate of the patent value (US$ 
33,079.75 million) from Table 14, which gives us 𝜇𝜇 = 0.03. For the upper bound, dividing the high 
estimate for R&D costs (US$ 1,210.54 million) and the low estimate of the patent value (US$ 22,294.26 
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million) implies 𝜇𝜇 = 0.05. This suggests that the theoretical innovation probability is well below 10 
percent – an astonishingly low figure. 
 
Table 17. Estimated R&D costs on subjects, site and study of Gardasil-4 and Gardasil-9 (in 2018 US$) 
  Estimate (in 2018 US$) 
  Gardasil-4 Gardasil-9 
  Low High Low High 
Ph
as
e-
I 
Total spent on subjects 94,069.77 376,279.07 18,372 73,488 
Total spent on sites 3,173,413.95 3,173,413.95 793,353.49 793,353.49 
Total spent of study costs 9,573,934.88 9,573,934.88 2,393,483.72 2,393,483.72 
Total spent on phase I clinical trials 12,841,418.60 13,123,627.91 3,202,637.21 3,250,037.21 
Ph
as
e-
II 
Total spent on subjects 1,684,186.05 2,245,581.40 1,068,488.37 1,424,651.16 
Total spent on sites 22,042,500.00 22,042,500.00 17,634,000.00 17,634,000.00 
Total spent of study costs 36,472,581.40 36,472,581.40 29,178,065.12 29,178,065.12 
Total spent on phase II clinical trials 60,199,267.44 60,760,662.79 47,880,553.49 48,236,716.28 
Ph
as
e-
III
 Total spent on subjects 107,539,534.88 161,309,302.33 77,297,674.42 115,946,511.63 
Total spent on sites 137,892,959.30 137,892,959.30 111,627,633.72 111,627,633.72 
Total spent of study costs 221,324,445.35 221,324,445.35 179,167,408.14 179,167,408.14 
Total spent on phase III clinical trials 466,756,939.53 520,526,706.98 368,092,716.28 406,741,553.49 
 Total spent on clinical trials 539,797,625.58 594,410,997.67 419,178,479.07 458,238,595.35 
Source: Own calculations based on Tables 15 and 16 jointly with Table A.1 for Gardasil-4 and Table A.2 
for Gardasil-9. 
 
Table 18. Total R&D cost derivation (in 2018 US$). 
  Low estimate High estimate 
Gardasil-4 (subjects, site, study) 539,797,626 594,410,998 
Gardasil-9 (subjects, site, study) 419,178,479 458,238,595 
Subtotal (subjects, site, study) 958,976,105 1,052,649,593 
Capital costs (15% of subtotal) 143,846,416 157,897,439 
Total Gardasil R&D costs 1,102,822,520 1,210,547,032 
Source: Own calculations based on Table 17. 
 
7. Conclusion 
Patent buyout is an effective strategy to lower vaccine prices, through allowing the entry of generic 
vaccines. We estimated that the remaining patent buyout value for Gardasil supplied by Merck in 2020 
to be between US$ 15.33 – 18.32 billion (in 2018 US$), depending on the assumed discount rate to 
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value the future profit stream and some uncertainty regarding manufacturing costs. The estimated 
patent buyout price may be viewed as upper bound since the original manufacturer Merck would still 
be able to make profits after the patent buyout because of its brand name and its established 
production capacity.  
Using information on clinical trials, we estimated the R&D costs for the Gardasil innovation to be 
around US$ 1.1 – 1.2 billion. Putting this into perspective to the total value of the Gardasil innovation, 
we arrive at a ratio of R&D costs to profits of the order of 3-5%.  
Our methodology may be seen as fruitful for future research. We would need many more studies for 
all kinds of pharmaceuticals on patent buyout prices that potentially could serve to tackle public health 
problems especially of developing countries. Moreover, more information of the relationship between 
R&D costs and innovation values we could be useful to ask whether current patent protection laws 
may be more generous than needed to elicit desirable R&D effort, thus burdening health systems more 
than necessary.  
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Appendix  
Table A.1. Estimated costs of R&D from phase I to phase III clinical trial for Gardasil-4. All costs in 
2018 US$.  
Ph
as
e 
# Description # of subjs 
Costs 
estimation 
per subject 
(US$) 
Calculated costs 
Low High Low High 
Ph
as
e 
I 
1** 
• In one study subjects were given four dose 
formulations of HPV11 L1 VLP vaccine (10, 20, 50, 
and 100 ug). There were 28 subjects per dose level 
and 28 for the placebo group 
• In the other study three different formulations 
were used to test HPV16 L1 VLPs: 10 ug (13 active 
and four placebo), 40 ug (45 active and 15 
placebo) and 80 ug (24 active and eight placebo).  
• Source: (Fife et al., 2004) 
249 116 465 28,953 115,814 
2** 
• Forty women, aged 16-23 years, were randomly 
assigned (2:1 vaccine to placebo ratio) to receive 
either HPV18 L1 VLP vaccine or placebo. 
•Source: (Ault et al., 2004) 
40 116 465 4,651 18,605 
3** 
• Healthy nonpregnant women aged 18 to 26 
years old were assigned to study groups to receive 
placebo or a 3-dose regime of the different HPV 16 
L1 VLP vaccine dosage of 10 μg (n=112), 20 μg 
(n=105), 40 μg (n=104), or 80 μg (n=107).  
• Source: (Poland et al., 2005) 
480 116 465 55,814 223,256 
4 
• Females aged 9-26 year were vaccinated with a 
single dose of Gardasil in an open label study to 
evaluate safety and tolerability of the vaccine. 
• From: March 2008-April 2008 
• ID: NCT00635830 
40 116 465 4,651 18,605 
Total spent on subjects on phase I 94,070 376,279 
Total spent on sites (number of studies x 793,353.49*) 3,173,414 3,173,414 
Total spent of study costs (number of studies x 2,393,483.72*) 9,573,935 9,573,935 
Total spent on phase I clinical trials 12,841,419 13,123,628 
Ph
as
e 
II 
1 
• Young women aged 16-23 years old were 
randomly assigned to receive three doses of 
placebo (n=1198) or HPV-16 virus-like–particle 
vaccine (n=1194) 
• From: September 1999- March 2004 
• ID: NCT00365378 
2,392 349 465 834,419 1,112,558 
2 
• A total of 831 women aged 16-23 years were 
vaccinated with one of the three formulations 
quadrivalent HPV (Types 6/11/16/18) L1 virus-like 
particle (VLP) (each of the 3 groups had 275-280 
subjects) or received one of the two placebo 
formulations (n=275). Dose escalation assessment 
(n=52). 
• From: May 2000-May 2004  
• ID: NCT00365716 
1,158 349 465 403,953 538,605 
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3 
• Women aged 18-26 years were assigned to 
receive Gardasil vaccination (n=509) or placebo 
(n=512) 
• From: June 2006-September 2009 
• ID: NCT00378560 
1,021 349 465 356,163 474,884 
4 
• Evaluate the effectiveness of Gardasil in men 
aged 27-45 who have completed 4 years of 
observation in HPV infection in men 
• Duration: December 2012 - October 2019 
• ID: NCT01432574 
150 349 465 52,326 69,767 
5 
• The immunogenicity, safety and tolerability of 
the quadrivalent vaccine was assessed in females 
Aged 9-17 years. 
• From: December 2006 - September 2009 
• ID: NCT00411749 
107 349 465 37,326 49,767 
Total spent on subjects on phase II 1,684,186 2,245,581 
Total spent on sites (number of studies x 4,408,500.00*) 22,042,500 22,042,500 
Total spent of study costs (number of studies x 7,294,516.28*) 36,472,581 36,472,581 
Total spent on phase II clinical trials 60,199,267 60,760,663 
Ph
as
e 
III
 
1 
• Women aged 16-24 year were randomly 
assigned to receive 3 doses of the quadrivalent 
vaccine (2723) or placebo (n=2732).  
• From: December 2001-January 2009; ID: 
NCT00092521  
5,455 2,326 3,488 12,686,047 19,029,070 
2 
• Women aged 16-23 were randomized (1:1:1:1) 
to receive three doses of quadrivalent HPV-
6/11/16/18 vaccine co-administered with HBV 
vaccine, quadrivalent vaccine with HBV-vaccine 
matched placebo, HBV vaccine with HPV-vaccine 
matched placebo, or HPV-vaccine matched 
placebo and HBV-vaccine matched placebo. 
• From: December 2001 - June 2004 
• ID: NCT00517309 
1,871 2,326 3,488 4,351,163 6,526,744 
3 
• Women aged 16-23 years in a phase III study to 
compare the immunogenicity and safety of the 
quadrivalent Gardasil and Monovalent HPV 16 
vaccine. 
• From: June 2002 - June 2004 
• ID: NCT00092482 
3,882 2,326 3,488 9,027,907 13,541,860 
4 
• Women aged 15-26 were randomly assigned 1:1 
to receive 3 doses of the quadrivalent vaccine or 
placebo 
• From: June 2002 - July 2007 
• ID: NCT00092534 
12,167 2,326 3,488 28,295,349 42,443,023 
5 
• Women age 10-23 years were randomly assigned 
to receive placebo or Gardasil to assess the 
immune response to the 4 components of the 
vaccine. 
• From: December 2002 - September 2004 
• ID: NCT00092495 
3,055 2,326 3,488 7,104,651 10,656,977 
 
 
31 
 
6 
• Adolescents aged 9 to 15 years were randomly 
assigned 2:1 to receive HPV4 vaccine or saline 
placebo. On the 30th, the placebo group (n = 482) 
received the same regimen of HPV4 vaccine and 
both cohorts were followed through month 96.  
• From: October 2003 - November 2005 
• ID: NCT00092547 
1,781 2,326 3,488 4,141,860 6,212,791 
7 
• Women aged 24-45 years were receive 3 doses 
of Gardasil (n=1911) or placebo (1908). 
• ID: NCT00090220 
• From: June 2004 - May 2009 
3,819 2,326 3,488 8,881,395 13,322,093 
8 
• Heterosexual males aged 16-24 (n=3463) and 
homosexual men aged 16–24 years (n= 602) were 
randomly assigned to receive three doses of 
Gardasil (n=2032) or placebo (n=2033). 
• From: September 2004 - July 2009 
• ID: NCT00090285 
4,065 2,326 3,488 9,453,488 14,180,233 
9 
• Females aged 9–23 years were randomly 
assigned to receive three doses of Gardasil (n=117) 
or placebo (n=59). 
• From: October 2005 - June 2006 
• ID : NCT00157950 
176 2,326 3,488 409,302 613,953 
10 
• Adolescents (394 boys and 648 girls) aged 10-17 
years were randomly assigned in a 1:1 ratio to 
receive: 3 doses of Gardasil with one dose of 
Menactra and Adacel (concomitant), 3 of Gardasil 
with one dose of Menactra and Adacel 
(nonconcomitant). 
• From: April 2006 - April 2007 
• ID: NCT00325130 
1,042 2,326 3,488 2,423,256 3,634,884 
11 
• Teenage boys and girls aged 11-17 were enrolled 
in an open-label study in which all subjects 
received three doses of GARDASIL and one of 
REPEVAX. 
• From: May 2006-May 2007 
• ID: NCT00337428 
843 2,326 3,488 1,960,465 2,940,698 
12 
• Women aged 9-15 years participated in the study 
to evaluate the safety and tolerability of Gardasil. 
• From: May 2007-February 2008 
• ID: NCT00380367 
110 2,326 3,488 255,814 383,721 
13 
• Chinese females aged 9-45 years (n=500) and 
males aged 9 to 15 years (n=100) were randomly 
assigned in a 1:1 ratio to receive either 3 doses of 
Gardasil or aluminum-containing placebo.  
• From: July 20, 2008-February 28, 2009 
• ID: NCT00496626 
600 2,326 3,488 1,395,349 2,093,023 
14 
• Females aged 20-45 years were assigned to 
receive three doses of Gardasil or placebo to test 
the safety and effectiveness of the vaccine. 
• From: December 31, 2008- May 11, 2012 
• ID: NCT00834106 
3,006 2,326 3,488 6,990,698 10,486,047 
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15 
• Sub-Saharan females aged 9-26 were enrolled in 
the study to evaluate safety, tolerability and 
immunogenicity of the three dose Gardasil. Thirty 
females ages 13-15 and 120 females ages 16-26 
received the three dose Gardasil. In addition, girls 
aged 9-12 years were randomized in a 4:1 ratio to 
receive either Gardasil (n = 80) or placebo (n = 20 
). 
• From: March 2011 - April 2013 
• ID: NCT01245764 
250 2,326 3,488 581,395 872,093 
16 
• Open label study to evaluate Gardasil`s safety 
and effectiveness in females aged 16- to 26 years. 
• From: November 2011-August 2016 
• ID: NCT01544478 
1,030 2,326 3,488 2,395,349 3,593,023 
17 
• Japanese males aged 16-26 year were enrolled in 
a study to evaluate the efficacy and tolerability of 
Gardasil. 
• From: June 2013 - August 2017 
• ID: NCT01862874 
1,124 2,326 3,488 2,613,953 3,920,930 
18 
• Evaluate the immunogenicity, safety, and 
tolerability of Gardasil in females aged 9-26 years  
• Duration: August 2018 - October 2023 
• ID: NCT03493542 
766 2,326 3,488 1,781,395 2,672,093 
19 
• Evaluate Two-dose schedule of Gardasil-4 in 11-
year-old Boys 
• Duration: February 2015 - December 2015 
• ID: NCT02382900 
500 2,326 3,488 1,162,791 1,744,186 
20 
• Evaluate tolerability and immunogenicity of a 3-
dose regimen of Gardasil administered to healthy 
married females aged 16-23 years  
• Duration: October 2009 - October 2013 
• ID: NCT00733122 
600 2,326 3,488 1,395,349 2,093,023 
21 
• Boys aged 9-15 years were enrolled in an open 
label two-part study in which part 1 assessed 
immunogenicity and tolerability of Gardasil up to 
Month 7 whereas part 2 assessed long-term 
immunogenicity and safety (Month 7-Month 30).  
• From: November 2015 - August 2018 
• ID: NCT02576054 
100 2,326 3,488 232,558 348,837 
Total spent on subjects on phase III 107,539,535 161,309,302 
Total spent on sites (number of studies x 6,566,331.40*) 137,892,959 137,892,959 
Total spent of study costs (number of studies x 10,539,259.30*) 221,324,445 221,324,445 
Total spent on phase III clinical trials 466,756,940 520,526,707 
 Total cost of all phases 539,797,626 594,410,998 
* From estimates displayed in Table 16.  
** Clinical trial was not registered on www.clinicaltrial.gov thus they do not have an ID. However, results were 
published in peer reviewed journals cited in the description (source). 
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Table A.2. Estimated costs of R&D from phase I to phase III clinical trial for Gardasil-9. All costs in 
2018 US$. 
Ph
as
e 
# Description # of subjs 
Costs 
estimation 
per subject 
(US$) 
Calculated costs 
Low High Low High 
Ph
as
e 
I 
1 
• Evaluate the safety and tolerability of 
octavalent HPV L1 VLP vaccine formulated with 
amorphous aluminum hydroxysulfate and 
ISCOMATRIX in females aged 18-24 years 
• Duration: April 2006 - November 2009 
• ID: NCT00851643 
158 116 465 18,372 73,488 
Total spent on subjects on phase I 18,372 73,488 
Total spent on sites (number of studies x 793,353.49*) 793,353 793,353 
Total spent of study costs (number of studies x 2,393,483.72*) 2,393,484 2,393,484 
Total spent on phase I clinical trials 3,202,637 3,250,037 
Ph
as
e 
II 
1 
• Determine immunogenicity, safety and 
tolerability of Gardasil-4 and 9 vaccine in young 
cancer survivors aged 9-26 years 
• Duration: July 2012 - November 2020 
• ID: NCT01492582 
1252 349 465 436,744 582,326 
2 
• Females aged 16-23 years were enrolled in a 
study to evaluate the tolerability and 
immunogenicity of the 3-dose vaccine. 
• From: December 2005 - August 2007 
• ID: NCT00260039 
680 349 465 237,209 316,279 
3 
• Compare safety and immunogenicity of V505 
HPV vaccine candidate and Gardasil-4 in females 
16-26 years 
• Duration: October 2007-May 2011 
• ID: NCT00520598 
511 349 465 178,256 237,674 
4 
• Examine tolerability and immunogenicity HPV 
L1 VLP vaccine candidate administered 
Concomitantly with Gardasil in females aged 16-
26. 
• Duration: October 2007 - May 2009 
• ID: NCT00551187 
620 349 465 216,279 288,372 
Total spent on subjects on phase II 1,068,488 1,424,651 
Total spent on sites (number of studies x 4,408,500.00*) 17,634,000 17,634,000 
Total spent of study costs (number of studies x 7,294,516.28*) 29,178,065 29,178,065 
Total spent on phase II clinical trials 47,880,553 48,236,716 
Ph
as
e 
III
  
1 
• A Phase III Open-label Safety and 
Immunogenicity Study of GARDASIL™9 
Administered to 9- to 26-Year-Old Females and 
Males in Vietnam 
• Duration: June 2018 - January 2019 
• ID: NCT03546842 
200 2,326 3,488 465,116 697,674 
2 
• This study will assess the safety and 
immunogenicity of GARDASIL®9 (V503) in 27- to 
45-year-old women 1212 2,326 3,488 2,818,605 4,227,907 
 
 
34 
 
• Duration: September 2017 - November 2018 
• ID: NCT03158220 
3 
• Examine the acceptability, uptake and 
immunogenicity of the vaccine in the postpartum 
setting in women 16 years to 26 years 
• Duration: November 2018 - July 2019 
• ID: NCT03451071 
200 2,326 3,488 465,116 697,674 
4 
• Assess occupational exposure to Human 
Papilloma Virus (HPV) and prophylactic 
vaccination in healthcare workers aged 27-69 
• Country: USA 
• Duration: February 2018 - November 2018 
• ID: NCT03350698 
100 2,326 3,488 232,558 348,837 
5 
• Evaluate the Immunogenicity of the nonvalent 
vaccine against Human Papillomavirus in men 
(age 18-36 years) infected by HIV who have sex 
with men. 
• Duration: October 2018 - December 2021 
• ID: NCT03626467 
166 2,326 3,488 386,047 579,070 
6 
• Assess the efficacy of HPV vaccine in reducing 
high-grade cervical lesions in patients with HPV 
and HIV infections in females aged 25 and older 
• Duration: January 2019 - October 2021 
• ID: NCT03284866 
536 2,326 3,488 1,246,512 1,869,767 
7 
• Assess the safety and immunogenicity of a 2-
dose regimen of Gardasil-9 (V503) in boys and 
girls 9 to 14 years of age and in young women 
aged 16-26 years  
• Duration: November 2013 - August 2018 
• ID: NCT01984697 
1518 2,326 3,488 3,530,233 5,295,349 
8 
• Assess safety, immunogenicity and long-term 
effectiveness Gardasil-9 in preventing cervical 
cancer and related precancers caused by HPV 
types covered in the vaccine in females aged 16-
26 years  
• Duration: January 2016 - January 2024 
• ID: NCT02653118 
4453 2,326 3,488 10,355,814 15,533,721 
9 
• Evaluate immunogenicity and tolerability of 
Gardasil-9 administered Concomitantly with 
Menactra and Adacel in boys and girls aged 11-15 
year 
• Duration: October 2009 - February 2011 
• ID: NCT00988884 
1241 2,326 3,488 2,886,047 4,329,070 
10 
• Evaluate tolerability of Gardasil-9 in females 
aged 12-26 years who were previously vaccinated 
with GARDASIL-4 
• Duration: February 2010 - November 2015 
• ID: NCT01047345 
924 2,326 3,488 2,148,837 3,223,256 
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11 
• Evaluate if Gardasil-9 induces non-inferior 
Geometric Mean Titres (GMTs) for serum anti-
HPV 6, 11, 16, and 18, compared to GARDASIL-4 
in males aged 16 – 26 year 
• Duration: March 2014 - April 2015 
• ID: NCT02114385 
500 2,326 3,488 1,162,791 1,744,186 
12 
• Compare immunogenicity and tolerability of 
Gardasil-4 and 9 in females ages 9-15 years 
• Duration: February 2011 - December 2011 
• ID: NCT01304498 
600 2,326 3,488 1,395,349 2,093,023 
13 
• Evaluate whether if first dose of Gardasil-9 
concomitantly administrated with REPEVAX™ is 
well tolerated and equally immunogenic 
compared to administration of REPEVAX a month 
after Gardasil-9 first dose 
• Countries: Finland, Germany, Denmark, 
Thailand, Belgium, Austria 
• Duration: April 2010 - June 2011 
• ID: NCT01073293 
1054 2,326 3,488 2,451,163 3,676,744 
14 
• Evaluate safety, tolerability and 
Immunogenicity of Gardasil-9 in Japanese girls 
aged 9-15 year 
• Duration: January 2011 - August 2013 
• ID: NCT01254643 
100 2,326 3,488 232,558 348,837 
15 
• Assess immunogenicity and tolerability of 
Gardasil-9 in males and females aged 9-15 years 
• Duration: August 2009 - December 2020 
• ID: NCT00943722 
3074 2,326 3,488 7,148,837 10,723,256 
16 
• Compare the safety, efficacy, and 
immunogenicity of Gardasil-4 and 9 in females 
aged 16-26 years old. 
• Duration: September 2007 - July 2016 
• ID: NCT00543543 
14840 2,326 3,488 34,511,628 51,767,442 
17 
• Evaluate immunogenicity and tolerability of 
Gardasil-9 in males and females aged 16-26 years 
• Duration: October 2012 - August 2014 
• ID: NCT01651949 
2520 2,326 3,488 5,860,465 8,790,698 
Total spent on subjects on phase III 77,297,674 115,946,512 
Total spent on sites (number of studies x 6,566,331.40*) 111,627,634 111,627,634 
Total spent of study costs (number of studies x 10,539,259.30*) 179,167,408 179,167,408 
Total spent on phase III clinical trials 368,092,716 406,741,553 
 Total costs of all phases 419,178,479.07 458,238,595.35 
* From estimates displayed in Table 16. 
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Supplementary Material 
 
Table B.1. Consumer price index (CPI) with base year 2015 and employed price index (PI) with base 
year 2018. 
Observation date CPI PI* 
2007-01-01 87.48 0.826 
2008-01-01 90.84 0.857 
2009-01-01 90.52 0.854 
2010-01-01 92.00 0.868 
2011-01-01 94.90 0.896 
2012-01-01 96.87 0.914 
2013-01-01 98.29 0.928 
2014-01-01 99.88 0.942 
2015-01-01 100.00 0.944 
2016-01-01 101.26 0.956 
2017-01-01 103.42 0.976 
2018-01-01 105.94 1.00 
* PI is given by CPI in a year with base year 2015 divided by CPI in 2018. 
Source: (Federal Reserve Bank, 2018) and own calculation. 
 
Table B.2. Detailed calculation for Table 11 of operating profits for different countries and country 
groups (a) 2007-2009, (b) 2010-2019 and (c) 2019-2027  
a) Operating profits estimation, 2007-2009 
   2007 2008 2009 
US
A 
Price (US$) 131.55 131.72 138.03 
Variable 
costs 
Low (US$) 1.00 1.00 1.00 
High (US$) 1.59 1.59 1.59 
# of doses (in millions) 10.42 9.50 7.25 
Profit 
High (US$) 1,360.59 1,241.45 993.64 
Low (US$) 1,354.45 1,235.85 989.36 
Ot
he
r H
IC
 
Price (US$) 45.96 45.96 45.96 
Variable 
costs 
Low (US$) 1.00 1.00 1.00 
High (US$) 1.59 1.59 1.59 
# of doses (in millions) 9.18 8.38 6.70 
Profit 
High (US$) 412.90 376.74 301.43 
Low (US$) 407.48 371.80 297.48 
Total profit per 
year (in million US$) 
High (US$) 1,773.49 1,618.19 1,295.07 
Low (US$) 1,761.93 1,607.64 1,286.84 
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b) Operating profits estimation, 2010-2019 
   Year 
   2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 
U.
S.
 
Price (US$) 137.61 126.16 127.99 130.76 139.17 148.96 163.57 164.47 164.47 137.61 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in 
millions) 6.32 8.18 10.66 11.54 10.13 10.81 11.39 9.75 8.84 9.10 
Profit (in 
million US$) 
High 863.61 1,023.76 1,353.26 1,497.51 1,399.41 1,599.55 1,850.93 1,593.48 1,588.83 1,635.56 
Low 859.88 1,018.93 1,346.97 1,490.71 1,393.44 1,593.17 1,844.22 1,587.73 1,583.62 1,630.19 
Ot
he
r H
IC
 
Price (US$) 45.96 45.96 45.96 45.96 45.96 45.96 45.96 45.96 45.96 45.96 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in 
millions) 9.34 12.70 7.61 5.86 5.10 3.98 4.27 5.91 5.95 6.12 
Profit (in 
million US$) 
High 419.83 570.98 342.30 263.41 229.14 178.90 192.16 265.79 267.30 275.17 
Low 414.32 563.49 337.80 259.95 226.14 176.55 189.64 262.30 263.80 271.55 
M
IC
 
Price (US$) 20.52 20.52 20.52 20.52 20.52 20.52 20.52 20.52 20.52 20.52 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in 
millions) 6.09 11.31 13.92 13.92 11.31 9.57 9.57 9.57 10.44 12.18 
Profit (in 
million US$) 
High 118.88 220.78 271.73 271.73 220.78 186.81 186.81 186.81 203.80 237.76 
Low 115.29 214.11 263.52 263.52 214.11 181.17 181.17 181.17 197.64 230.58 
GA
VI
 
Price (US$)    4.69 4.69 4.69 4.69 4.69 4.69 4.69 
Variable costs 
(US$) 
Low    1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High    1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in 
millions) 0.00 0.00 0.00 0.87 0.87 1.74 2.61 1.74 5.22 23.49 
Profit (in 
million US$) 
High    3.21 3.21 6.42 9.62 6.42 19.25 86.62 
Low    2.69 2.69 5.39 8.08 5.39 16.17 72.76 
In
do
ne
sia
/I
nd
ia
 
Price (US$)       11.28 11.28 11.28 11.28 
Variable costs 
(US$) 
Low       1.00 1.00 1.00 1.00 
High       1.59 1.59 1.59 1.59 
# of doses (in 
millions) 0.00 0.00 0.00 0.00 0.00 0.00 0.87 0.87 0.87 0.87 
Profit (in 
million US$) 
High       8.94 8.94 8.94 8.94 
Low       8.43 8.43 8.43 8.43 
Profit per year (in 
million US$) 
High 1,402.32 1,815.52 1,967.28 2,035.86 1,852.54 1,971.68 2,248.48 2,061.45 2,088.13 2,244.06 
Low 1,389.49 1,796.53 1,948.29 2,016.87 1,836.38 1,956.28 2,231.54 2,045.02 2,069.65 2,213.52 
 
 
 
 
 
47 
 
c) Operating profit estimation, 2020-2027 
   2020 2021 2022 2023 2024 2025 2026 2027 
U.
S.
 
Price (US$) 137.61 126.16 127.99 130.76 139.17 148.96 163.57 164.47 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 9.88 9.36 8.84 8.32 7.80 7.28 7.28 7.28 
Profit (in 
million US$) 
High 1,350.38 1,172.05 1,123.15 1,080.10 1,078.26 1,077.67 1,184.07 1,190.63 
Low 1,344.54 1,166.53 1,117.94 1,075.19 1,073.66 1,073.38 1,179.77 1,186.33 
Ot
he
r H
IC
 
Price (US$) 45.96 45.96 45.96 45.96 45.96 45.96 45.96 45.96 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 6.65 6.30 5.95 5.60 5.25 4.90 4.90 4.90 
Profit (in 
million US$) 
High 298.75 283.03 267.30 251.58 235.86 220.13 220.13 220.13 
Low 294.83 279.31 263.80 248.28 232.76 217.24 217.24 217.24 
M
IC
 
Price (US$) 20.52 20.52 20.52 20.52 20.52 20.52 20.52 20.52 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 13.05 13.05 13.05 13.05 13.92 14.79 14.79 14.79 
Profit (in 
million US$) 
High 254.75 254.75 254.75 254.75 271.73 288.71 288.71 288.71 
Low 247.05 247.05 247.05 247.05 263.52 279.99 279.99 279.99 
GA
VI
 
Price (US$) 4.69 4.69 4.69 4.69 4.69 4.69 4.69 4.69 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 34.80 26.97 28.71 31.32 21.75 27.84 26.10 25.23 
Profit (in 
million US$) 
High 128.33 99.45 105.87 115.49 80.20 102.66 96.24 93.04 
Low 107.79 83.54 88.93 97.01 67.37 86.23 80.84 78.15 
In
do
ne
sia
/I
nd
ia
 Price (US$) 11.28 11.28 11.28 11.28 11.28 11.28 11.28 11.28 
Variable costs 
(US$) 
Low 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
High 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 0.87 13.92 25.23 23.49 24.36 21.75 20.01 18.27 
Profit (in 
million US$) 
High 8.94 143.12 259.40 241.51 250.45 223.62 205.73 187.84 
Low 8.43 134.90 244.51 227.65 236.08 210.78 193.92 177.06 
Ch
in
a 
Price (US$)   159.38 159.38 159.38 159.38 159.38 159.38 
Variable costs 
(US$) 
Low   1.00 1.00 1.00 1.00 1.00 1.00 
High   1.59 1.59 1.59 1.59 1.59 1.59 
# of doses (in millions) 0 0 0.87 2.61 3.48 3.48 4.35 6.09 
Profit (in 
million US$) 
High   137.79 413.36 551.15 551.15 688.93 964.50 
Low   137.27 411.82 549.09 549.09 686.36 960.91 
Profit per year (in 
million US$) 
High 2,041.14 1,952.39 2,148.26 2,356.79 2,467.65 2,463.94 2,683.81 2,944.85 
Low 2,002.65 1,911.33 2,099.49 2,307.00 2,422.48 2,416.72 2,638.13 2,899.68 
Source: Own calculations based on Tables 3, 4, 6a, 10. 
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Abstract
Human papillomavirus (HPV) is responsible for almost all of the 530,000 new cases of cervical cancer and approximately 
266,000 deaths per year. HPV vaccination is an integral component of the World Health Organization’s global strategy 
to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion, 
particularly in low- and middle-income countries. This raises the question of the patent buyout price for Merck’s HPV 
vaccines (Gardasil-4 and 9), which hold 87% of the global HPV vaccine market. It also raises the question about the 
market power from patent protection, that we assess by estimating the ratio of R&D costs for Gardasil and its patent 
value. We estimate the patent buyout price for various groups of countries and in total. The estimated global Gardasil 
patent buyout price in 2020 is between US$ 15.33 – 18.32 billion (in 2018 US$), the estimated present discounted 
value of the profit stream for 2007-2028 amounts to US$ 22.29 – 33.08 billion, and the estimated total R&D cost is 
between US$ 1.10 – 1.21 billion. Thus, we arrive at a ratio of R&D costs to the patent value of the order of 3-5%, 
suggesting that patent protection provides Merck with extraordinarily strong market power.
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